Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

Publication | Closed Access

DOI

346

Citations

References

2012

Year

Edwin DeJesus, Jürgen K. Rockstroh, Keith Henry, Jean‐Michel Molina, Joseph Gathe, S. Ramanathan, Xuelian Wei, Kitty Yale, Javier Szwarcberg, Kirsten White,

The Lancet

Hiv/aids CounsellingTreatment And PreventionMedicineAntiviral Drug DevelopmentClinical TrialsAntiviral TherapyVirologyCo-formulated ElvitegravirPharmacotherapyAntiviral DrugHivPharmacologyAntiviral CompoundCo-formulated EmtricitabinePhase 3